Revenue Ahead of Guidance
Q1 revenue of $50.2M, above guidance of $48M-$49M; full-year guidance reaffirmed at $220M-$230M (13%-19% YoY growth) with expected annualized run-rate revenue >$250M by Q4.
LifeMD
· LFMD
May 6th, 2026
Summary
- Earnings Call Date:
- 2026-05-06
- Change Since:
- -14.61%
- Next Earnings Date:
- 2026-08-06
Earnings Call Sentiment
PositiveThe call presents a constructive operational narrative: record subscriber additions, strong momentum in weight management and Women’s Health, meaningful gross margin expansion, growing pharmacy and insurance scale, and a clear roadmap to leverage AI for operating leverage. These positives are balanced against near-term profitability pressures from a front-loaded marketing push, a product‑mix transition from compounded to branded drugs that dampened near‑term revenue/unit economics, a wider GAAP net loss, and negative adjusted EBITDA in Q1. Management reaffirmed full-year guidance and outlined drivers for a second‑half EBITDA ramp (insurance coverage expansion, pharmacy economics, cross-sell, and marketing normalization), indicating confidence in the outlook despite short-term investments and transitions.
Company Guidance
Management reaffirmed full-year 2026 guidance of $220–$230 million in revenue (≈13–19% YoY) and $12–$17 million in adjusted EBITDA, and reiterated a goal of annualized run-rate revenue above $250 million and adjusted EBITDA above $25 million by Q4; Q2 guidance is $47–$50 million in revenue and adjusted EBITDA of negative $2 million to positive $1 million with a return to adjusted EBITDA profitability expected in H2. For context, Q1 actuals included $50.2 million revenue, ~42k net subscriber adds (ending >365k active subscribers, +~26% YoY), an adjusted EBITDA loss of ~$4.5 million, GAAP net loss of $9.6 million ($0.20/sh), gross profit $44.2 million with gross margin of 88% (up ~420 bps), selling & marketing $29.8 million, stock‑based comp $1.4 million, cash of $34.5 million, no debt and a $30 million undrawn revolver. Other operational metrics cited: ~100k weight‑management patients, ~215k RexMD active patients, pharmacy processing ~20k scripts/month from a 22.5k sq ft facility, ~112 million covered lives at quarter end (expected ~230 million by month‑end), CAC improved 4–5% sequentially as volumes rose from ~300–400 to 600–1,000 new patients/day, Women’s Health subscribers grew >7x from Q4 with on‑therapy retention >80%, RexMD personalized ED meds +>40% vs Q4, and marketing is expected at ~$26–27 million in Q2 with combined Q3–Q4 marketing of ~$42–44 million.
Record Subscriber Additions and Subscriber Growth
Largest quarterly net addition in company history with ~42,000 net telehealth subscribers in Q1; active subscribers grew ~26% year-over-year to over 365,000 at quarter end.
Weight Management Momentum
Weight management sign-ups rose ~120% sequentially from Q4; ended the quarter with just under 100,000 weight management patients; customer acquisition costs (CAC) improved ~4%-5% sequentially even as daily new patient volumes roughly doubled (from ~300-400/day to ~600-1,000/day).
Women’s Health Rapid Early Growth
Women’s Health subscribers grew more than 7x from the Q4 base; on-therapy retention is tracking north of 80%; plans to introduce seven new compounded pharmacy products supporting hormone and bone health.
RexMD Scale and Category Expansion
RexMD has ~215,000 active patients with growth across ED, sleep (fastest-growing), and hair loss; personalized ED medications (sildenafil + tadalafil) grew >40% versus Q4 and in-house fulfillment is expected to drive margin expansion.
Gross Margin Expansion and Gross Profit Growth
Gross margin expanded ~420 basis points to 88% in Q1, driven by lower shipping/fulfillment costs and scaling in-house pharmacy; gross profit was $44.2M, up ~3% year-over-year despite flat revenue.
Pharmacy & Coverage Scale
Affiliated pharmacy operating a 22.5k sq ft facility licensed in all 50 states, processing ~20k prescriptions/month with capacity to expand; covered lives expanded from ~112M at quarter end to an expected ~230M by end of the month, enabling broader insurance-supported access (Medicare GLP-1 Bridge launching July 1).
Capital Position and Balance Sheet Flexibility
Exited the quarter with $34.5M in cash, no debt, and a $30M undrawn revolving credit facility, providing flexibility to fund growth initiatives.
AI and Operating Leverage Roadmap
Management is deploying AI across intake, documentation, clinical decision support, revenue cycle and back-office workflows to increase provider capacity and improve margins; expects margin impact to become more visible in 2026.
Operator
Good afternoon. Thank you for joining us today to discuss LifeMD, Inc.'s results for the first quarter ended 03/31/2026. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer, and Atul Kavikar, Chief Financial Officer. Following management’s prepared remarks, we will open the call for a question-and-answer session. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the company’s 10-Ks and 10-Q filings and within other filings that LifeMD, Inc. may make with the SEC from time to time. Forward-looking statements made during this call are based on certain information available to the company as of today, 05/06/2026.
The company assumes no obligation to update or revise any forward-looking statements after today’s call except as required by law. Also, please note that management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD, Inc.’s performance. Details on the relationship between these non-GAAP measures and the most comparable GAAP measures, and a reconciliation thereof, can be found in the press release issued earlier today. Finally, I would like to remind everyone that today’s call is being recorded and will be available for replay in the Investor Relations section of the company’s website. Now I would like to turn the call ove...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free